Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IN8bio Inc. Common Stock
INAB | US
0.47
USD0.20
75.28%
INAB | US
About IN8bio Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
0.47
Open
0.28
High
0.56
Low
0.27
IN8bio Inc. a clinical-stage biopharmaceutical company focuses on the discovery development and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200 a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100 an allogeneic product candidate which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400 which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300 INB-410 and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics Inc. and changed its name to IN8bio Inc. in August 2020. IN8bio Inc. was incorporated in 2016 and is headquartered in New York New York.
View LessINAB | US
Risk
284.2
Sharpe
-0.36
Luna's Score
51/100
Recommendation
Hold
Luna says (INAB | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
374.5%1 month
284.2%3 months
182.6%6 months
153.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.23
Debt to equity
0.43
Debt to assets
0.26
Ent. to EBITDA
-1.15
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-30.63M
MarketCap
34.46M
MarketCap(USD)
34.46M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-180.45
Short ratio
0.44
Short perc.
0.61
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.34
Range1M
0.34
Range3M
0.67
Volumes: Market Activity
Rel. volume
15.76
Price X volume
14.97M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.15 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.23 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 182.65 | 72.80 | Riskier |
| Debt to Equity | 0.43 | -1.23 | Expensive |
| Debt to Assets | 0.26 | 0.25 | Par |
| Market Cap | 34.46M | 3.66B | Emerging |
